Biodexa Pharmaceuticals (BDRX) Cash from Operations (2013 - 2022)

Biodexa Pharmaceuticals has disclosed Cash from Operations across 8 years of filings, most recently posting $35187.8 for Q4 2022.

• In Q4 2022, Cash from Operations rose 100.84% year-over-year to $35187.8; the TTM figure through Dec 2022 stood at -$15.4 million (down 110.17% YoY), while the FY2025 annual figure was -$7.4 million, up 52.96% from the prior year.
• Cash from Operations came in at $35187.8 for Q4 2022 at Biodexa Pharmaceuticals, up from -$4.4 million in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of $35187.8 in Q4 2022 to a low of -$6.9 million in Q4 2018.
• Average Cash from Operations over 3 years is -$3.9 million, with a median of -$4.3 million recorded in 2021.
• Year-over-year, Cash from Operations plunged 414.55% in 2018 and soared 100.84% in 2022.
• Over 3 years, Cash from Operations stood at -$6.9 million in 2018, then surged by 39.35% to -$4.2 million in 2021, then surged by 100.84% to $35187.8 in 2022.
• Per Business Quant data, the three most recent Cash from Operations figures were $35187.8 in Q4 2022, -$4.4 million in Q3 2022, and -$4.2 million in Q4 2021.